Thyroid Cancer Pipeline

DelveInsight’s, “Thyroid Cancer Pipeline Insight, 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Thyroid Cancer Understanding

Thyroid Cancer Overview

Thyroid cancer is a malignant condition that primarily arises from the follicular cells of the thyroid gland, which are responsible for producing thyroid hormones. The symptoms of thyroid cancer include a neck lump, hoarseness, difficulty swallowing, and swollen lymph nodes, though many early cases are asymptomatic.  Thyroid cancer risk is influenced by a combination of genetic, environmental, and lifestyle factors. The most well-established cause is exposure to ionizing radiation, particularly during childhood, which significantly raises the likelihood of developing thyroid malignancies. Inherited genetic syndromes such as MEN2, Cowden syndrome, and familial medullary thyroid cancer also contribute to increased risk. Women are more commonly affected, possibly due to hormonal influences like estrogen. Lifestyle and environmental factors, including obesity, low iodine intake, and exposure to pollutants, may also play a key role. 

Thyroid cancer is classified into four main types, namely papillary, follicular, medullary, and anaplastic thyroid cancers, with papillary being the most common and least aggressive. Follicular cancer is slightly more aggressive and tends to spread to distant organs like the lungs and bones. Medullary thyroid cancer originates from C cells, is less common, and is often linked to inherited syndromes such as MEN2. Anaplastic thyroid cancer is the rarest and most aggressive form, typically affecting older individuals and associated with a poor prognosis.

Diagnosis of Thyroid cancer has significantly advanced through innovations in imaging, cytology, molecular testing, and artificial intelligence. Ultrasound remains the first-line tool, especially when guided by TI-RADS, while CT and PET/CT help assess lymph node involvement and distant spread. Fine-needle aspiration cytology (FNAC), often combined with thyroglobulin washout (FNA-Tg), enhances diagnostic sensitivity, particularly for lymph node metastases. Molecular diagnostics, including tests for BRAF, RET, and RAS mutations, are crucial when cytology is inconclusive and help guide personalized treatment. Emerging technologies like Raman spectroscopy and machine learning offer high diagnostic accuracy and the potential to detect malignancy earlier and more precisely. The integration of imaging and genetic data through radiogenomics further refines risk assessment and supports precision oncology approaches. 

Thyroid cancer treatment involves a personalized, multidisciplinary approach tailored to cancer type, stage, and molecular profile. Surgery remains the primary treatment, with total thyroidectomy commonly performed. Radioactive iodine therapy is used post-surgery for differentiated cancers but is ineffective in medullary and anaplastic types. Thyroid hormone suppression therapy helps prevent recurrence by lowering TSH levels. For advanced or iodine-resistant cancers, targeted therapies such as TKIs and mutation-specific inhibitors like selpercatinib offer promising outcomes. The emerging strategies include radiofrequency ablation and precision monitoring based on molecular testing to guide ongoing care and improve quality of life.

"Thyroid Cancer Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Thyroid Cancer pipeline landscape is provided which includes the disease overview and Thyroid Cancer treatment guidelines. The assessment part of the report embraces, in depth Thyroid Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Thyroid Cancer pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Thyroid Cancer Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Thyroid Cancer.

Thyroid Cancer Emerging Drugs Analysis

This segment of the Thyroid Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Thyroid Cancer Emerging Drugs

AL2846: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

AL-2846 is an investigational small-molecule kinase inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. It targets receptor protein-tyrosine kinases, aiming to block cancer cell growth. The current trials are focused on its use in iodine-refractory differentiated thyroid cancer (both alone and in combination with other therapies), neurofibromatosis type 1 (NF1), and pancreatic cancer. The drug is being evaluated under Phase III stage of its clinical trial for the treatment of Thyroid Cancer.

Vemurafenib: Genentech

Vemurafenib (Zelboraf) is an oral, small molecule, BRAF kinase inhibitor. The BRAF protein is a key component of the RAS-RAF pathway involved in normal cell growth and survival. Mutations that keep the BRAF protein in an active state may cause excessive pathway signalling, leading to uncontrolled cell growth and survival. Vemurafenib is designed to block the BRAF gene mutation. By blocking this mutation, the drug may kill the cancer cells with the mutation and/or stop the tumor from growing. The drug is currently in Phase II stage of its clinical trial for the treatment of Thyroid Cancer. 

ST-1898: Beijing Scitech-Mq Pharmaceuticals Limited

ST-1898 is an investigational oral, multi-targeted tyrosine kinase inhibitor being developed by Beijing Scitech-Mq Pharmaceuticals Limited for the treatment of advanced cancers, including thyroid cancer. It targets multiple signaling pathways such as VEGFR2, c-MET, AXL, RET, and KIT, which are involved in tumor growth and angiogenesis. The drug is currently being evaluated in a Phase II clinical trial for patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer who have failed prior therapies. Its multi-target mechanism aims to overcome resistance to existing treatments and improve clinical outcomes in difficult-to-treat thyroid cancer populations. The drug is currently being evaluated under Phase II stage of its clinical trial for the treatment of Thyroid Cancer. 

AIC100: AffyImmune Therapeutics

AIC100 is an affinity‑tuned, third‑generation CAR‑T cell therapy engineered to target ICAM‑1 on advanced thyroid cancers, including anaplastic (ATC) and poorly differentiated (PDTC) types. ICAM-1, found on the surface of cancer cells, acts as a binding site for LFA-1 on AIC100 CAR T cells, facilitating their recognition and destruction of malignant cells. AffyImmune has chosen anaplastic and advanced differentiated thyroid cancers as the initial indication for AIC100 and has received Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy Designations from the FDA. The drug is currently in Phase I stage of its clinical trial for the treatment of Thyroid Cancer. 

Further product details are provided in the report……..

Thyroid Cancer Therapeutic Assessment

This segment of the report provides insights about the different Thyroid Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Thyroid Cancer Players in Thyroid Cancer

There are approx. 45+ key companies which are developing the therapies for Thyroid Cancer. The companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. Phase III include, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Thyroid Cancer Clinical Trial Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Thyroid Cancer Drug Route of Administration

Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Thyroid Cancer Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Thyroid Cancer Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Thyroid Cancer Clinical Trial Activities

The Thyroid Cancer Pipeline report provides insights into different Thyroid Cancer Clinical Trials within Phase III, II, I, preclinical and discovery stage. It also analyses Thyroid Cancer therapeutic drugs key players involved in developing key drugs. 

Thyroid Cancer Pipeline Development Activities

The Thyroid Cancer Clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid Cancer drugs.

Thyroid Cancer Report Insights

• Thyroid Cancer Pipeline Analysis
• Thyroid Cancer Therapeutic Assessment
• Thyroid Cancer Unmet Needs
• Impact of Thyroid Cancer Drugs

Thyroid Cancer Report Assessment

• Thyroid Cancer Pipeline Product Profiles
• Thyroid Cancer Therapeutic Assessment
• Thyroid Cancer Pipeline Assessment
• Thyroid Cancer Inactive drugs assessment
• Thyroid Cancer Market Unmet Needs

Discover actionable insights into the Thyroid Cancer market trends, epidemiology trends, and forecast through 2032 to stay ahead in emerging therapies.

Key Questions Answered In The Thyroid Cancer Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Thyroid Cancer drugs?
• How many Thyroid Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thyroid Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Thyroid Cancer therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Thyroid Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Thyroid Cancer Key Companies

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Genentech
• Sichuan Kelun-Biotech Biopharmaceutical
• AffyImmune Therapeutics
• Bayer
• Gilead Sciences
• Model Medicines
• Biovista
• Xynomic Pharmaceuticals
• TYK Medicines
• Solve Therapeutics
• Pfizer
• Fore Biotherapeutics
• Beijing Scitech-Mq Pharmaceuticals Limited
• Sunshine Lake Pharma Co., Ltd.

Thyroid Cancer Key Products

• AL2846
• Vemurafenib 
• A400
• AIC100
• Regorafenib
• Sacituzumab govitEcan
• MDL-4101
• BVA 701
• XP-102
• TY-1091
• SLV-154
• PF-07799933
• FORE8394
• ST-1898
• HEC169096

Explore comprehensive insights into Thyroid Cancer epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.